Zeo ScientifiX, Inc.

Zeo ScientifiX, Inc. (ZEOX) and Pluri Inc. (PLUR) announced a definitive strategic agreement to expand their U.S. manufacturing and commercialization platform for regenerative medicine, aesthetics, wellness, and longevity markets. The partnership combines Pluri's cell technology and clinical development expertise with Zeo's established U.S. biologics manufacturing capabilities and physician network. Under the agreement, Pluri will grant Zeo rights to its regenerative medicine assets, and Zeo will issue shares representing 50% ownership of the company to Pluri post-closing. The deal also includes exclusive U.S. rights to Pluri's CellaV aesthetic product line. The transaction is expected to close in the fourth quarter of 2026.

Zeo ScientifiX, Inc. announced the launch of ZEO Xperience, its inaugural three-day immersive educational program for healthcare professionals. This event, scheduled for October 23–25, 2026, in Fort Lauderdale, aims to enhance knowledge of regenerative biologics, strengthen clinical expertise, and provide best practices for integrating advanced biologic therapies. The program will feature evidence-based scientific education, hands-on clinical training, and business development strategies.

Zeo ScientifiX announced efforts to strengthen its role within South Florida’s healthcare innovation ecosystem. The company is focusing on regenerative biologic research and development, physician education, and scientific collaboration. Operating from Nova Southeastern University’s Center for Collaborative Research, Zeo ScientifiX aims to connect emerging science with healthcare professionals and support responsible advancement in regenerative medicine.

Zeo ScientifiX reported exceptional financial results for the quarter and six months ended April 30, 2026. The company achieved a 124.6% year-over-year revenue growth for the quarter, reaching $2,581,000, and a 79.9% increase for the six-month period, totaling $4,027,000. Gross margins remained strong at approximately 80.0%, and the net loss significantly decreased to $1.0 million for the six months, compared to $2.6 million in the prior year.

Zeo ScientifiX announced it will host a live virtual educational webinar for healthcare professionals on July 22, 2026. Titled "One Year Later, Three States Stronger: The Southeast Regen Revolution," the webinar will discuss lessons from Florida's stem cell law and its implications for physicians in other states like Tennessee and Georgia as regenerative medicine expands. The event aims to advance physician education and foster evidence-based discussions on responsible innovation, featuring a panel of scientific, medical, and regulatory experts.

Zeo ScientifiX announced that it donated products to support a humanitarian medical mission in Cusco, Peru. Dr. Constantino Mendieta, a member of ZEO's Medical Advisory Board, participated in the 10-day mission, providing specialized reconstructive care to approximately 38 child patients recovering from severe burn injuries using the donated products. The initiative reflects the company's commitment to physician-led care and expanding access to advanced therapeutic options.

Zeo ScientifiX, Inc. (ZEOX) filed its Form 10-Q for the period ending April 30, 2026. The company reported a significant increase in revenues to $4,027,000 for the first six months of the fiscal year, up from $2,239,000 in the prior year. This revenue growth contributed to a reduced net loss of $997,000, an improvement from $2,634,000 in the same period last year. The company also recognized a $390,000 gain from the sale of its Exotropin interests. Despite these improvements, the company continues to face challenges related to its going concern status, with substantial doubt expressed about its ability to continue operations without additional funding.

Zeo ScientifiX, Inc. awarded a total of 3,830,000 stock options under its 2021 Incentive Stock Plan on June 10, 2026. These options were granted to Greyt Ventures LLC, CEO Ian Bothwell, CMO George Shapiro, and non-executive director Chuck Bretz. The awards include both immediately vested options and performance-based incentive options, all with an exercise price of $1.67 per share.

Zeo ScientifiX, Inc. announced the expansion of its Medical Advisory Board with the addition of nine highly-recognized physicians and scientific innovators. This move strengthens the company's scientific leadership across key disciplines in regenerative and longevity medicine, including orthopedics, oncology, and pain management. The expanded board will focus on advancing scientific rigor, clinical standards, and physician education as access to regenerative medicine grows in the United States.

Zeo ScientifiX, Inc. announced the formal launch of its Physician-Led Patient Masterclass program. This initiative is designed to empower physicians to educate their patient populations on regenerative medicine, addressing a significant demand for information. The program formalizes a model that emerged organically from a physician-organized event and follows the company's training of over 600 physicians in regenerative therapies across the Southeast.